Particle.news
FDA Approval GLP-1 Drugs Regulatory Approval Patient Safety Efficacy Studies Treatment Options Obesity Treatments Patient Outcomes
Ulefnersen, targeting FUS gene mutations, demonstrates safety, biomarker reduction, and functional recovery in early clinical use, with a global trial underway.
